Non-small Cell Lung Cancer Clinical Trial
Official title:
89Zr-pembrolizumab-PET Imaging in Patients With Locally Advanced or Metastatic Melanoma or Non-small Cell Lung Cancer
Verified date | May 2024 |
Source | University Medical Center Groningen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a two center, single arm, investigator sponsored trial (IST) with the PET tracer 89Zr-pembrolizumab to evaluate in vivo whole body distribution of 89Zr-Pembrolizumab in a registered indication: locally advanced metastatic melanoma or non-small cell lung cancer before Pembrolizumab treatment.
Status | Completed |
Enrollment | 18 |
Est. completion date | September 2020 |
Est. primary completion date | March 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age =18 years. 2. Histologically or cytologically documented locally advanced or metastatic melanoma or NSCLC. 3. Patients must be eligible for treatment with Pembrolizumab. For patients with NSCLC this includes PD-L1 expression (>1% based on IHC assay) on tumor material. 4. Metastatic lesion(s) (=1,0 cm) of which a histological biopsy can safely be obtained according to standard clinical care procedures. 5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. 6. Life expectancy = 12 weeks . 7. Signed Informed Consent Form. 8. Ability to comply with protocol. 9. Measurable disease, as defined by standard RECIST v1.1. Previously irradiated lesions should not be counted as target lesions. 10. Adequate hematologic and end organ function, defined by the following laboratory results obtained within = 14 days prior to 89Zr-pembrolizumab injection: - Absolute Neutrophil Count (ANC) = 1500 cells/µL (without granulocyte colony-stimulating factor support within 2 weeks prior to 89Zr-pembrolizumab injection) - White Blood Count (WBC) = 2500/µL - Lymphocyte count = 500/µL - Platelet count = 100,000/µL (without transfusion within 2 weeks prior to 89Zr-Pembrolizumab injection) - Hemoglobin =9.0 g/dL. Patients may be transfused or receive erythropoietin treatment to meet this criteria. - Asparate Aminotransferase (AST), Alanine Aminotransferase (ALT), and alkaline phosphatase =2.5 x the Upper Limit of Normal (ULN), with the following exceptions: - Patients with documented liver metastases: AST and/or ALT = 5 x ULN - Patients with documented liver or bone metastases: alkaline phosphatase = 5 x ULN - Serum bilirubin = 1.5 x ULN. Patients with known Gilbert disease who have serum bilirubin level =3 x ULN may be enrolled. - International Normalized Ratio (INR) and Activated Partial Thromboplastin Time (aPTT) =1.5 x ULN. This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose. - Creatinine clearance =30 mL/min 11. For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly). Exclusion Criteria: 1. Any approved anti-cancer therapy, including chemotherapy of hormonal therapy within =14 days prior to 89Zr-pembrolizumab injection; the following exceptions are allowed: • Hormone-replacement therapy or oral contraceptives. 2. Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to the 89Zr-pembrolizumab injection. 3. Malignancies other than melanoma or NSCLC within 5 years prior to 89Zr-pembrolizumab injection, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated with curative intent or ductal carcinoma in situ treated surgically with curative intent). 4. Pregnant and lactating women. 5. Symptomatic brain metastasis. 6. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins. 7. Known hypersensitivity or allergy to any component of the pembrolizumab formulation. 8. History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. - Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study. - Patients with controlled Type I diabetes mellitus on a stable dose of insulin regimen may be eligible for this study. 9. Positive test for Human Immunodeficiency Virus (HIV). 10. Patients with active hepatitis B (chronic or acute; defined as having a positive hepatitis B surface antigen [HBsAg] test at screening) or hepatitis C. - Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBcAb] and absence of HBsAg) are eligible. HBV DNA test must be performed in these patients prior to 89Zr-Pembrolizumab injection. - Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. 11. Signs or symptoms of infection within 2 weeks prior to 89Zr-pembrolizumab injection. 12. Major surgical procedure other than for diagnosis within 28 days prior to 89Zr-pembrolizumab injection or anticipation of need for a major surgical procedure during the course of the study. 13. Prior allogeneic bone marrow transplantation or solid organ transplant. 14. Treatment with corticosteroids in an increasing dosage in the 7 days prior to 89Zr-pembrolizumab injection. (A stable or decreasing dosage of = 1,5 mg dexamethasone or = 10 mg prednisolone equivalent is allowed. In addition, inhaled or topical steroids and adrenal replacement doses are permitted in the absence of active autoimmune disease.) 15. Inability to comply with other requirements of the protocol. |
Country | Name | City | State |
---|---|---|---|
Netherlands | Netherlands Cancer Institute | Amsterdam | |
Netherlands | University Medical Center Groningen | Groningen |
Lead Sponsor | Collaborator |
---|---|
University Medical Center Groningen |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Description of whole body 89Zr-pembrolizumab by measuring standardized uptake value (SUV) on the 89Zr-pembrolizumab-PET scans | 1 year | ||
Secondary | Tumor and immune cell PD-L1 expression analysis in a fresh pre-treatment biopsy, and if available archival tumor biopsy, will be correlated to 89Zr-pembrolizumab tumor uptake, evaluated by measuring SUV on the 89Zr-pembrolizumab-PET. | 1 year | ||
Secondary | Safety assessment through summaries of adverse events, changes in laboratory test results, changes in vital signs, and exposure to 89Zr-pembrolizumab. Adverse event data will be recorded and summarized according to NCI CTCAE v4.0. | Safety assessment through summaries of adverse events, changes in laboratory test results (if evaluation is indicated), changes in vital signs, and exposure to 89Zr-pembrolizumab. Adverse event data will be recorded and summarized according to NCI CTCAE v4.0. Serious adverse events, including deaths, will be listed separately and will be summarized. For events of varying severity, the highest grade will be used in summaries. Relevant laboratory tests and vital signs (heart rate, respiratory rate, blood pressures, and temperature) data will be displayed by time, with Grade 3 and 4 values identified, where appropriate. | 1 year | |
Secondary | 89Zr-pembrolizumab normal organ uptake on the 89Zr-pembrolizumab PET scans will be correlated to (89Zr-)pembrolizumab blood kinetics. | 89Zr-pembrolizumab normal organ uptake on the 89Zr-pembrolizumab PET scans will be correlated to (89Zr-)pembrolizumab blood kinetics. Aliquots of whole blood and serum will be measured for 89Zr-activity in an isotope well counter and corrected for decay. Whole blood and serum activity will be expressed as standardized uptake value (SUV). Serum blood samples will also be collected regularly during the study to measure unlabeled pembrolizumab. PK parameters will be derived from the serum concentrations. | 1 year | |
Secondary | Evaluation of ORR according to standard RECIST v1,1 | Evaluation of ORR according to standard RECIST v1,1. ORR is defined as the proportion of subjects whose best overall response is either a PR or CR. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |